About
Allogeneic corneal endothelial cell therapy combined with a ROCK inhibitor; launched in Japan (end 2024) and in Phase 1/2 in the US. One of the leading cell-therapy plays in ophthalmology.
HQ: (US/Japan)
Funding
$150M+ disclosed to date
—Company profile
Corneal endothelial cell therapy to restore vision in sight-threatening corneal disease.
Allogeneic corneal endothelial cell therapy combined with a ROCK inhibitor; launched in Japan (end 2024) and in Phase 1/2 in the US. One of the leading cell-therapy plays in ophthalmology.
HQ: (US/Japan)